Interaction of brequinar and analogs with PD-L1: a molecular docking analysis
Aim: The immunosuppressive drug brequinar (BQR) is a potent inhibitor of dihydroorotate dehydrogenase (DHODH) active against autoimmune diseases and viral infections. This oral drug is currently evaluated for the treatment of cancers, notably acute myeloid leukemia to limit the suppressive function...
Saved in:
| Main Authors: | Gérard Vergoten, Christian Bailly |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration
2025-06-01
|
| Series: | Exploration of Drug Science |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/uploads/Article/A1008113/1008113.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Uncovering a novel binding trench in ERRα: insights from molecular simulations
by: Lamees Hegazy, et al.
Published: (2025-02-01) -
Co-folding, the future of docking – prediction of allosteric and orthosteric ligands
by: Eva Nittinger, et al.
Published: (2025-12-01) -
Exploration of structural space of Cus17 lectin with glycans using molecular docking and simulation studies
by: Vikas Tiwari, et al.
Published: (2025-01-01) -
In-silico screening, molecular docking, pharmacokinetics studies and design of histone deacetylase inhibitors as anti-Alzheimer agents
by: ABDULJELIL Ajala, et al.
Published: (2022-02-01) -
Accurate prediction of protein–ligand interactions by combining physical energy functions and graph-neural networks
by: Yiyu Hong, et al.
Published: (2024-11-01)